A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses.

Autor:	Cimen Bozkus C; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10127, USA., Blazquez AB; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10127, USA.; Global Biological Specimen and Imaging Management (GBS&IM), Bristol Myers Squibb, Princeton, NJ 08540, USA., Enokida T; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10127, USA.; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Bhardwaj N; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10127, USA.
Jazyk:	angličtina
Zdroj:	STAR protocols [STAR Protoc] 2021 Aug 17; Vol. 2 (3), pp. 100758. Date of Electronic Publication: 2021 Aug 17 (Print Publication: 2021).
DOI:	10.1016/j.xpro.2021.100758
Abstrakt:	Determining the antigen specificities of the endogenous T-cell repertoire is important for screening naturally occurring or therapy-induced T-cell immunity and may help identify novel targets for T-cell-based therapies. Here, we describe a rapid, sensitive, and high-throughput protocol for expanding antigen-specific T cells from human peripheral blood mononuclear cells in vitro following peptide stimulation and detecting antigen-specific effector cytokine formation by flow cytometry. Our approach can be applied to examining specific T-cell subsets from various tissues. For complete details on the use and execution of this protocol, please refer to Roudko et al. (2020) and Cimen Bozkus et al. (2019). Competing Interests: N.B. is an extramural member of the Parker Institute for Cancer Immunotherapy, receives research funds from 10.13039/100009857Regeneron, Harbor Biomedical, DC Prime, and Dragonfly Therapeutics, and is on the advisory boards of Neon Therapeutics, Novartis, Avidea, Boehringer Ingelheim, Rome Therapeutics, Roswell Park Comprehensive Cancer Center, BreakBio, Carisma Therapeutics, CureVac, Genotwin, BioNTech, Gilead Therapeutics, Tempest Therapeutics, and the Cancer Research Institute. C.C.B. is a Bridge Scholar of the Parker Institute for Cancer Immunotherapy. N.B. and C.C.B. have a patent application (application no. 17/290,128), which utilizes the T-cell immunogenicity assay protocol described here. A.B.B. is currently an employee of Bristol Myers Squibb. T.E. declares no interests. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu